Effect of papaverine on developmental hyperserotonemia induced autism spectrum disorder related behavioural phenotypes by altering markers of neuronal function, inflammation, and oxidative stress in rats

Cilostazol as adjunctive therapy in treatment of children with autism spectrum disorders: a double-blind and placebo-controlled randomized trial

We aimed to evaluate cilostazol therapeutic effects on aberrant behaviors of autism spectrum disorder (ASD) children and its safety profile in a double-blind, randomized clinical trial. Sixty-six children with confirmed ASD were allocated to receive either daily 50-mg cilostazol (increased to 100 mg/day after 2 weeks) or matched placebo in addition to risperidone. The Aberrant Behavior Checklist-Community Edition (ABC-C) scale and a checklist of probable adverse effects were used to assess the behavioral outcomes and safety profile at weeks 0, 5, and 10 of the study. Sixty-one participants, with comparable baseline characteristics, completed the trial. Unlike other ABC-C subscales, repeated-measures analysis showed significant effect for time × treatment interaction in the hyperactivity subscale ( P = 0.047; partial eta squared = 0.06). We used the median value for the baseline score hyperactivity subscale [median (interquartile range) = 31 (24-37)] to stratify participants to higher hyperactivity and lower hyperactivity subgroups and found that only participants with higher hyperactivity benefit from cilostazol adjunctive therapy ( P = 0.028; partial eta squared = 0.14). Cilostazol could be considered as a safe agent with beneficial effects on hyperactivity in children with ASD and higher levels of hyperactivity.

Implication of Hippocampal Neurogenesis in Autism Spectrum Disorder: Pathogenesis and Therapeutic Implications

Autism spectrum disorder (ASD) is a cluster of heterogeneous neurodevelopmental conditions with atypical social communication and repetitive sensory-motor behaviors. The formation of new neurons from neural precursors in the hippocampus has been unequivocally demonstrated in the dentate gyrus of rodents and non-human primates. Accumulating evidence sheds light on how the deficits in the hippocampal neurogenesis may underlie some of the abnormal behavioral phenotypes in ASD. In this review, we describe the current evidence concerning pre-clinical and clinical studies supporting the significant role of hippocampal neurogenesis in ASD pathogenesis, discuss the possibility of improving hippocampal neurogenesis as a new strategy for treating ASD, and highlight the prospect of emerging pro-neurogenic therapies for ASD.

Vinpocetine, a PDE1 modulator, regulates markers of cerebral health, inflammation, and oxidative stress in a rat model of prenatal alcohol-induced experimental attention deficit hyperactivity disorder

Prenatal alcohol exposure (PAE) has been shown to induce symptomatology associated with attention deficit hyperactivity disorder (ADHD) by altering neurodevelopmental trajectories. Phosphodiesterase-1 (PDE1) is expressed centrally and has been used in various experimental brain conditions. We investigated the role of vinpocetine, a PDE1 inhibitor, on behavioral phenotypes and important biochemical deficits associated with a PAE rat model of ADHD. Protein markers of cerebral health (synapsin-IIa, BDNF, and pCREB), inflammation (IL-6, IL-10, and TNF-α), and oxidative stress (TBARS, GSH, and SOD) were analyzed in three brain regions (frontal cortex, striatum, and cerebellum). Hyperactivity, inattention, and anxiety introduced in the offspring due to PAE were assayed using open-field, Y-maze, and elevated plus maze, respectively. Administration of vinpocetine (10 & 20 mg/kg, p.o. [by mouth]) to PAE rat offspring for 4 weeks resulted in improvement of the behavioral profile of the animals. Additionally, levels of protein markers such as synapsin-IIa, BDNF, pCREB, IL-10, SOD, and GSH were found to be significantly increased, with a significant reduction in markers such as TNF-α, IL-6, and TBARS in selected brain regions of vinpocetine-treated animals. Vinpocetine, a selective PDE1 inhibitor, rectified behavioral phenotypes associated with ADHD, possibly by improving cerebral function, reducing brain inflammation, and reducing brain oxidative stress. This study provides preliminary analysis and suggests that the PDE1 enzyme may be an important pharmacological tool to study ADHD as a result of PAE.

Development of a Dy2O3@Eu2O3-carbon nanofiber based electrode for highly sensitive detection of papaverine

A sensitive electrochemical method based on carbon nanofibers (CNFs) and bimetallic nanoparticles of dysprosium oxide (Dy₂O₃) and europium oxide (Eu₂O₃) was developed for the determination of papaverine in pharmaceuticals and human urine. Several electrodes were compared in respect to their electrochemically active surface area calculated as 0.0603, 0.1300, 0.3440, 0.3740 and 0.4990 cm² for bare GCE, CNFs/GCE, Eu₂O₃-CNFs/GCE, Dy₂O₃-CNFs/GCE and Dy₂O₃@Eu₂O₃-CNFs/GCE, respectively. Electrodes were also compared in respect to their performance towards the voltammetric process of papaverine. The peak potential (Epa) of papaverine was 1.094 V, 0.993 V, 0.978 V, 0.969 V and 0.966 V at unmodified GCE, CNFs/GCE, Eu₂O₃-CNFs/GCE, Dy₂O₃-CNFs/GCE and Dy₂O₃@Eu₂O₃-CNFs/GCE, respectively. This indicated that the oxidation peak potential of papaverine shifted gradually towards the negative potentials and the peak current increased gradually from unmodified GCE to CNFs/GCE, Eu₂O₃-CNFs/GCE, Dy₂O₃-CNFs/GCE and Dy₂O₃@Eu₂O₃-CNFs/GCE. The influence of experimental parameters such as scan rate and pH on the voltammetry of papaverine was studied. The Dy₂O₃@Eu₂O₃-CNFs/GCE system presented a dynamic working range between 1.0 × 10^-7 and 2.0 × 10^-6 M with a detection limit of 1.0 × 10^-8 M for papaverine. The platform (Dy₂O₃@Eu₂O₃-CNFs/GCE) exhibited excellent sensitivity and selectivity for papaverine in the presence of uric acid and was successfully applied for determining papaverine in pharmaceuticals and urine samples.